<DOC>
	<DOCNO>NCT00185211</DOCNO>
	<brief_summary>This study primarily compare long-term effect early continue treatment Betaferon/Betaseron ( patient treat active medication double-blind BENEFIT study ) treatment initiate either Clinically Definite Multiple Sclerosis ( CDMS ) diagnose two year ( patient treat placebo double-blind BENEFIT study ) . Analyses base integrate data initial BENEFIT study follow-up study .</brief_summary>
	<brief_title>BENEFIT Study ( Betaferon® / Betaseron® Newly Emerging Multiple Sclerosis Initial Treatment ) BENEFIT Follow-up Study</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer HealthCare Pharmaceuticals Inc.. Bayer HealthCare Pharmaceuticals Inc. sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients reach scheduled end study BENEFIT , either develop CDMS complete 24 month No participation initial BENEFIT study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>